-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ki7kzfdJR09XiLfV2UUxLfUI/c5GtB1dT3cIFGdwxtI03g42s9ihERwbO8t0a6fo
 9wedaeWwHQz3DdwXThnKlw==

<SEC-DOCUMENT>0001130319-06-000192.txt : 20060316
<SEC-HEADER>0001130319-06-000192.hdr.sgml : 20060316
<ACCEPTANCE-DATETIME>20060316110628
ACCESSION NUMBER:		0001130319-06-000192
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060316
FILED AS OF DATE:		20060316
DATE AS OF CHANGE:		20060316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		06690463

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o30661e6vk.htm
<DESCRIPTION>FORM 6-K DATED MARCH 16, 2006
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 6-K dated March 16, 2006</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of March 2006

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Press Release</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: March 16, 2006</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Brad Thompson
<HR size="1" noshade width="60%">
Brad Thompson<BR>
President and CEO</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "Press Release" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="top">
        <TD width="70%"><IMG src="o30661o3066100.gif" alt="Oncolytics Biotech Logo"></TD>
        <TD width="30%">210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt"><B><HR align="left" size="1" width="100%" noshade></B>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>FOR IMMEDIATE RELEASE</B>

</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>Oncolytics Biotech Inc.&#146;s Research Collaborators to<BR>
Present REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Clinical Trial Data at ASCO Conference</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, &#151; March&nbsp;16, 2006 </B>&#151; Research collaborators with Oncolytics Biotech Inc.
(&#147;Oncolytics&#148;) (TSX:ONC, NASDAQ:ONCY) are scheduled to deliver two poster presentations covering
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> clinical trial data at the American Society of Clinical Oncology (ASCO)&nbsp;Annual Meeting,
to be held June 2-6, 2006 in Atlanta, Georgia. The data cover interim results of Oncolytics&#146; Phase
I systemic administration trial being conducted in the U.K., and final results of Oncolytics&#146;
Canadian Phase I recurrent malignant glioma trial.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A poster entitled &#147;A Phase I study of a wild-type reovirus (Reolysin) given intravenously to
patients with advanced malignancies&#148; is scheduled to be presented by Dr.&nbsp;Johann S. de Bono of The
Royal Marsden Hospital and The Institute of Cancer Research, U.K.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A poster entitled &#147;A phase I trial of intratumoral (i.t.) administration of reovirus in patients
with histologically confirmed recurrent malignant gliomas (MGs)&#148; is scheduled to be presented by
Dr.&nbsp;P.A. Forsyth of the University of Calgary and the Alberta Cancer Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I and
Phase I/II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human reovirus, alone
and in combination with radiation. For further information about Oncolytics, please visit
<U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
implication of the materials to be presented at this meeting with respect to REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, the
Company&#146;s expectations related to the results of trials investigating delivery of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, and
the Company&#146;s belief as to the potential of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer therapeutic, involve known and
unknown risks and uncertainties, which could cause the Company&#146;s actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects,
the efficacy of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer treatment, the success and timely completion of clinical
studies and trials, the Company&#146;s ability to successfully commercialize REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, uncertainties
related to the research and development of pharmaceuticals, uncertainties related to the regulatory
process and general changes to the economic environment. Investors should consult the Company&#146;s
quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements.</I>
</DIV>




<P align="left" style="font-size: 10pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Oncolytics Biotech Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Cathy Ward</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">210, 1167 Kensington Cr NW</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Toronto Street</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Calgary, Alberta T2N 1X7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toronto, Ontario M5C 2B8</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Tel: 403.670.7377</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 416.815.0700 ext. 226</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Fax: 403.283.0858</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 416.815.0080</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>cathy.ward@oncolytics.ca</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>www.oncolyticsbiotech.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">The Investor Relations Group</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RenMark Financial Communications</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Damian McIntosh</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">John Boidman</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">11 Stone Street, 3rd Floor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2080 Rene Levesque Blvd. W.</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">New York, NY 10004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montreal, PQ H3H&nbsp;1R6</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 514.939.3989</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 514.939.3717</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top"><U>dmcintosh@investorrelationsgroup.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>jboidman@renmarkfinancial.com</U></TD>
</TR>
</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o30661o3066100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o30661o3066100.gif
M1TE&.#=A\@`W`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#R`#<`0`C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQXL05@:ZQNA9HA44`*Q!MO&;EH\F3*%.J7#G1RC5H
MK%@B7`&MU369.'/JW+ERA2R./`^RFA53Z$\K&UEY'&AE%DF$20-%M/*S*,)2
M-J4:I`K482!H&I<"&'FH(:N?8A-RU5IP!2MHLYY`#"2+E56(*S3>Y:GBVBQH
M">U>2\MTZ%.%5@(9UJC1U*&2"!,/A0LWFBQ37`@31'HMVK7/H#]K)JAG5K2R
M$">/+LB9[4&,II(R9G6H(T&,BD./9&7*MMFJJRM::65MENO`@:PD/FZ0BRF%
M>=,>5CB8H6+ED)$_9)5<.;3L%?,N_T2*=`52A0:F!S7_=98UXNXM$TT>/*C]
M^_CS1W3K_EHK67"Q4DH@!-K%BF<;_>2;?@PVZ"!.*U@6#7@K!6+97@]FJ.&&
M`N5&(4]T3<CAB"3BEY1^/EF#H4!OS2(6%S8I585-'P(0XHK0P:2>03Y%,\N'
M5)TV46Z"1&18?0(%B5I!@L6`DGD;>:90(._AJ));&R%9XI9<RI312`LZA*5_
MUM38Y9EHIJGFFFSF9P47N<'U6516:-GFG7@^Q%E2=3YD'F-$V9GGH&M^N:-)
MAII)Z*)<[FG`3C&P\IZ@C%:*GUL:75J5I9QN>&)^*YBV)).R7'A0%QLI"M)N
MW.5VC2QF(O^55*N(R,F*HJTU]*52!V54%Y.R!3O;H;DFY"HKB`12BF"\LK8;
M@8I-9MQKIC$7%'$XOG63C<4URUF-&<&TWU_5)=0CK%N5.JJN51EF+53N::GD
M08Q12E"T?FGTV`KUY6;O28$09^90+K*&H%.Q(JBJ4)^9B6DK@!R$E)`2[?%3
MD:DY)>^!ZPI4PB%@'?*ON0=:LQI5X@85@#66C=SIRRQQ5JY,@/QGY4`>N;P0
MOPWE#%+//_>L95HD/,F0RSP_*=BA$F'$V+M"=9=8?8GM+/4>"[,HK]2JKG`%
M(-BIH%"S8^E\V\T`G`>2(%`+A!%VJI;7TDM$S<D=W'"R0AQ\,)G_#?/?@`<N
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M59T$M8+BE**`FH.7-0+0H6BHR".V`]>K7N@VOUB#!0HI`>F`U,2(2-`:9&R1
MO-IX&Q4*!U^>T==J0(@?(<[B>P;9"#328CM6L(!E-8I07?ZU*R8"Z`!;>141
MW:B151@)&K*0ER2=.(M)GL0MLFC%!9]HO?<\BF&#W(H@T169R=RJ3MAQ3B)S
MTQW$28:!$GO5*^&FG/IPP3)73`U<-'D98UVOEMC!'T'XU$M8T@67QN/>0ZY0
MJK:)32%%PPL*88>X%5PS=-T4$PNWN1`R23.$8\S>\OBT$S"I4WJ&PLEP$/G!
M6RD&=('H6%ON1E@>SM%%?PBY9W<6XKZI44<L2PP/!U.H%;69JZ!D)%F,SIFV
M:[PG>MQAX4()L@=]4C`[/H$"0T1IG8Z0TR`$>@A)$)?0TVV4*=A#"B!N5@+5
ML40V#]23[Z;U-,Z>MN4OH511UAJ7+[M0U*>+VY-?X/*>]W3&&F1J12F<A-2J
3^JF;B"N!5;?*U:YZ]:OV"0@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
